Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

No central action of CGRP antagonising drugs in the GTN mouse model of migraine

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

DOI

  1. Headache provocation by nitric oxide in men who have never experienced a headache

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Prevalence of neck pain in migraine: A systematic review and meta-analysis

    Publikation: Bidrag til tidsskriftReviewpeer review

  1. Headache provocation by nitric oxide in men who have never experienced a headache

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Reply to 'Paracetamol use in pregnancy - neglecting context promotes misinterpretation'

    Publikation: Bidrag til tidsskriftLetterpeer review

  3. Low adherence to the guideline for the acute treatment of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  4. Polygenic risk provides biological validity for the ICHD-3 criteria among Finnish migraine families

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Vis graf over relationer

INTRODUCTION: Clinically, calcitonin gene-related peptide antagonising drugs are recognized as effective in migraine treatment, but their site of action is debated. Only a small fraction of these compounds pass the blood-brain barrier and accesses the central nervous system. Regardless, it has been argued that the central nervous system is the site of action. Here, we test this hypothesis by bypassing the blood-brain barrier through intracerebroventricular injection of calcitonin gene-related peptide antagonising drugs.

METHODS: We used the glyceryl trinitrate (GTN) mouse model, which is well validated by its response to specific migraine drugs. The calcitonin gene-related peptide receptor antagonist olcegepant and the calcitonin gene-related peptide monoclonal antibody ALD405 were administered either intraperitoneally or intracerebroventricularly. The outcome measure was cutaneous mechanical allodynia.

RESULTS: Mice given olcegepant intraperitoneally + GTN on day 1 had a mean 50% withdrawal threshold of 1.2 g in contrast to mice receiving placebo + GTN, which had a threshold of 0.3 g (p < 0.001). Similarly, in the ALD405 + GTN group, mice had thresholds of 1.2 g versus 0.2 g in the placebo + GTN group (p < 0.001). However, both drugs were ineffective when delivered intracerebroventricularly, as control and active groups had identical mechanical sensitivity thresholds, 0.2 g versus 0.1 g and 0.1 g versus 0.1 g for olcegepant and ALD405, respectively (p > 0.99 in both cases).

DISCUSSION: The site of action of olcegepant and of the monoclonal antibody ALD405 is outside the blood-brain barrier in this mouse model of migraine. It is likely that these results can be generalised to all gepants and all antibodies and that the results are relevant for human migraine.

OriginalsprogEngelsk
TidsskriftCephalalgia : an international journal of headache
Vol/bind40
Udgave nummer9
Sider (fra-til)924-934
Antal sider11
ISSN0333-1024
DOI
StatusUdgivet - aug. 2020

ID: 60054621